Koutsokera A, Corriveau S, Sykes J, et al. - Researchers assessed the safety and efficacy of omalizumab for asthma or allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF) in the Toronto adult CF center. They evaluated alterations in FEV₁% predicted (FEV₁pp; forced expiratory volume in 1 s % predicted) max value, slope and variability captured by the area under the curve (AUC), the cumulative dose of systemic corticosteroids (SCS), use of intravenous antibiotics and hospitalization days prior to omalizumab and up to 1 year posttreatment start. Findings revealed no significant omalizumab-related adverse effects. Omalizumab resulted in improvement in the max value of FEV₁pp and reduction in the cumulative dose of SCS in the asthmatic group. It caused improvement in the rate of FEV₁pp decline (slope) and the variability of FEV₁pp (AUC) in the ABPA group. Considering omalizumab in adult CF patients with difficult-to-treat asthma or ABPA was recommended.